Top Recruiting Trials
20 actively recruiting studies
Aim 3 Particle Swarm Optimization PIGD
University of Minnesota
n=30
University of Minnesota
Minneapolis, Minnesota
Intervention DEVICE: DBS — Deep Brain Stimulation
Eligibility Ages 18 Years – 85 Years
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
n=1264
Clearview Cancer Institute
Huntsville, Alabama
Intervention DRUG: LY3537982 — Administered orally.
Eligibility Ages 18 Years
Physical Activity in Persons With Parkinson's Disease
Karolinska Institutet
n=50
Karolinska institutet
Stockholm, Solna
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
Unity Health Toronto
n=45
Unity Health Toronto
Toronto, Ontario
Intervention DIAGNOSTIC_TEST: PET scans — PET scans and PHNO scans
Eligibility Ages 25 Years – 55 Years
Longitudinal Cognitive Assessment by BoCA
Alzheimer's Light LLC
n=10000
Andrey Vyshedskiy
Miami, Florida
Intervention DIAGNOSTIC_TEST: Boston Cognitive Assessment (BoCA) — The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring...
Eligibility Ages 50 Years
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Gruppo Oncologico Italiano di Ricerca Clinica
n=142
Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
Aviano (PN)
Intervention DRUG: Atezolizumab — 1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase
Eligibility Ages 18 Years
Robot-assisted Walking Treatment in Hereditary Spastic Paraplegia (HSP)
IRCCS Eugenio Medea
n=50
Irccs Eugenio Medea
Bosisio Parini, Italy/lecco
Intervention DEVICE: Robot-Assisted Gait Training — 15 sessions of robot-assisted gait training(LOKOMAT)+ 15 session of usual treatment for a total of 30 sessions in three ...
Eligibility Ages 4 Years – 70 Years
Validation of the REMINDER Dementia Risk Reduction Program
University of Coimbra
n=400
Faculty of Psychology and Educational Sciences
Coimbra
Intervention BEHAVIORAL: REMINDER — The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to st...
Eligibility Ages 60 Years – 75 Years
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
AMO Pharma Limited
n=76
Arkansas Children's Hospital
Little Rock, Arkansas
Intervention DRUG: Tideglusib — Tideglusib dosing will be weight-adjusted at 400 mg, 600 mg, or 1000 mg dose levels, or weight banded fixed doses of 400...
Eligibility Ages 6 Years – 45 Years
Contact Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM · AMO Pharma
Semantic Recognition Task (SRT) in Alzheimer Disease
Istanbul University
n=80
Jbid Dursun Uncu
Beşiktaş, Istanbul
Intervention BEHAVIORAL: Semantic Recognition Procedure — A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall pha...
Nomad P-KAFO Study
Shirley Ryan AbilityLab
n=36
Shirley Ryan AbilityLab
Chicago, Illinois
Intervention DEVICE: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH) — The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement ...
Eligibility Ages 18 Years – 89 Years
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Darcy Krueger
n=64
University of Alabama at Birmingham
Birmingham, Alabama
Intervention DRUG: Sirolimus — The investigational drug product to be used in this study is sirolimus, provided in oral suspension.
Eligibility Ages 1 Day – 6 Months
A Study for HSK39775 in Participants With Solid Tumors
Xizang Haisco Pharmaceutical Co., Ltd
n=243
Fundan University Shanghai Cancer Center
Shanghai, Shanghai Municipality
Intervention DRUG: HSK39775 Monotherapy — HSK39775 will be administered orally once daily
Eligibility Ages 18 Years
Effectiveness of the Safe Haven Application (App) Among Undergraduates
National Cheng-Kung University Hospital
n=68
National Cheng Kung University
Tainan
Intervention BEHAVIORAL: Safe Haven App — A Just-in-Time Adaptive Intervention (JITAI) mobile app that integrates self-monitoring, risk stratification, and tailor...
Eligibility Ages 18 Years – 24 Years
Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson's Disease: Development and Application
Fujian Medical University Union Hospital
n=700
Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
Fuzhou, Fujian
Eligibility Ages 40 Years – 80 Years
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
CellSight Technologies, Inc.
n=20
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Intervention DRUG: [18F]F-AraG — Two PET scans
Eligibility Ages 18 Years
Acupuncture and Moxibustion for Motor Symptoms in Early Parkinson's Disease
Jiani Wu
n=60
Guang'anmen Hospita, China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality
Intervention PROCEDURE: Acupuncture and Moxibustion (AM) — Acupuncture and moxibustion group (AM): Acupuncture at Shuifen (CV9), bilateral Yinlingquan (SP9), bilateral Zhongliao (...
Eligibility Ages 30 Years – 80 Years
Effects of Motor Imagery Training
Kahramanmaras Sutcu Imam University
n=50
Kahramanmaraş Sütçü imam University
Kahramanmaraş, Onikişubat
Intervention OTHER: Mental Imagery Application Protocol — Before the GYKO test, the patient will be asked to perform mental imagery to visualize a 3-meter distance for five cycle...
Eligibility Ages 40 Years – 75 Years
Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease
University Hospital, Grenoble
n=70
CHU Grenoble Alpes
Grenoble
Eligibility Ages 18 Years
RASopathy Biorepository
Children's Hospital Medical Center, Cincinnati
n=1000
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio